InsiderSignal.AI

InsiderSignal.ai

PVLA - Palvella Therapeutics, Inc.

Insider Purchase by Heron Elaine J (Dir)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

1 month ago, Heron Elaine J, serving as Dir at Palvella Therapeutics, Inc. (PVLA), purchased 2,400 shares at $125.00 per share, for a total transaction value of $300,000.00. Following this transaction, Heron Elaine J now holds 53,691 shares of PVLA.

This purchase represents a 5.00% increase in Heron Elaine J's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, February 27, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 2, 2026, 3 days after the trade was made.

Palvella Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Heron Elaine J

Dir

Elaine J. Heron, Ph.D. is a seasoned life sciences executive serving as an independent Director at Palvella Therapeutics, Inc. (NASDAQ: PVLA), a clinical-stage biopharmaceutical company developing therapies for serious rare skin diseases.[[1]](https://www.pachyonychia.org/palvella-newexecutive/)[[3]](https://palvellatx.com/about/)[[4]](https://fintool.com/app/research/companies/VXRT/people/elaine-j-heron) Appointed to the Palvella board in 2018, she brings extensive expertise in rare diseases, commercial leadership, finance, and R&D, and recently purchased 2,400 shares for $300,000 on February 27, 2026, increasing her direct ownership to 47,812 shares.[[1]](https://www.pachyonychia.org/palvella-newexecutive/)[[2]](https://au.investing.com/news/insider-trading-news/heron-elaine-j-palvella-therapeutics-director-buys-300000-in-shares-93CH-4286492)[[5]](https://www.sahmcapital.com/news/content/palvella-therapeutics-director-elaine-j-heron-acquires-common-shares-2026-03-02) Dr. Heron holds a B.S. in chemistry (highest distinction), a Ph.D. in analytical biochemistry from Purdue University, and an MBA from Pepperdine University.[[4]](https://fintool.com/app/research/companies/VXRT/people/elaine-j-heron) Her career highlights include serving as Chair and CEO of Amplyx Pharmaceuticals (acquired by Pfizer in 2021) from 2009 to 2015 and Labcyte Inc. from 2001 to 2008, as well as General Manager and VP of Sales/Marketing at Applied Biosystems.[[4]](https://fintool.com/app/research/companies/VXRT/people/elaine-j-heron) She currently holds board positions at public companies like Vaxart (since 2022), BioMarin Pharmaceutical (since 2002), and others including Visgenx, BlueWhale Bio, and Zephyrus Biosciences.[[4]](https://fintool.com/app/research/companies/VXRT/people/elaine-j-heron)[[6]](https://www.marketscreener.com/insider/ELAINE-HERON-A04P1S/)

View full insider profile →

Trade Price

$125.00

Quantity

2,400

Total Value

$300,000.00

Shares Owned

53,691

Trade Date

Friday, February 27, 2026

52 days ago

SEC Filing Date

Monday, March 2, 2026

Filed 3 days after trade

HEALTHCAREBIOTECHNOLOGY

About Palvella Therapeutics, Inc.

Company Overview

No company information available
View news mentioning PVLA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4429452

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime